Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.

Hamad F, Elnour AA, Elamin A, Mohamed S, Yousif I, Don J, Abdi S, Al Amoodi A, Fathelrahman AI, Gnana K, Alanzi F, Abubakar AB, Magboul SM, Ahmed SA, Sadeq A

Current diabetes reviews1 Jan 2021Cited by 12 (Europe PMC)

PMID32867644DOI10.2174/1573399816999200821164129PepBankPUB-32867644

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with heart failure and reduced ejection fraction, the FIGHT trial found no significant between-group difference in global rank scores between liraglutide and placebo.
In plain wordsIn people with heart failure, liraglutide did not change the global rank score compared with placebo in the FIGHT trial.
Peptide
Liraglutide
Outcome
No significant changeGlobal rank score (FIGHT trial)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
mean rank
146 rank
liraglutide
mean rank
156 rank
placebo
Source sentences
Summary
In the FIGHT trial the primary intention-to-treat, sensitivity, and diabetes subgroup analyses have shown no significant between-group difference in the global rank scores (mean rank of 146 in the liraglutide group versus 156 in the placebo group; Wilcoxon rank-sum P=.31)
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764401
02HumanSystematic reviewEfficacy outcome
In adults with heart failure and reduced ejection fraction, the FIGHT trial found no significant between-group difference in number of deaths with liraglutide versus placebo.
In plain wordsIn people with heart failure, liraglutide did not change the number of deaths compared with placebo in the FIGHT trial.
Peptide
Liraglutide
Outcome
No significant changeNumber of deaths (FIGHT trial)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
no significant between-group difference in the global rank scores (mean rank of 146 in the liraglutide group versus 156 in the placebo group; Wilcoxon rank-sum P=.31), number of deaths
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764402
03HumanSystematic reviewEfficacy outcome
In adults with heart failure and reduced ejection fraction, the FIGHT trial found no significant between-group difference in heart failure re-hospitalizations with liraglutide versus placebo.
In plain wordsIn people with heart failure, liraglutide did not change hospital readmissions for heart failure compared with placebo in the FIGHT trial.
Peptide
Liraglutide
Outcome
No significant changeHeart failure re-hospitalizations (FIGHT trial)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
no significant between-group difference in the global rank scores (mean rank of 146 in the liraglutide group versus 156 in the placebo group; Wilcoxon rank-sum P=.31), number of deaths, re-hospitalizations for heart failure
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764403
04HumanSystematic reviewEfficacy outcome
In adults with heart failure and reduced ejection fraction, the FIGHT trial found no significant between-group difference in the composite of death or change in NT-proBNP with liraglutide versus placebo.
In plain wordsIn people with heart failure, liraglutide did not change the combined outcome of death or NT-proBNP change compared with placebo in the FIGHT trial.
Peptide
Liraglutide
Outcome
No significant changeComposite of death or change in NT-proBNP (FIGHT trial)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
no significant between-group difference in the global rank scores (mean rank of 146 in the liraglutide group versus 156 in the placebo group; Wilcoxon rank-sum P=.31), number of deaths, re-hospitalizations for heart failure, or the composite of death or change in NT-pro BNP level (P= .94).
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764404
05HumanSystematic reviewEfficacy outcome
In adults with heart failure and reduced ejection fraction, the LIVE trial found no significant difference in the change in left ventricular ejection fraction between liraglutide and placebo.
In plain wordsIn people with heart failure, liraglutide did not change heart pumping fraction differently from placebo in the LIVE trial.
Peptide
Liraglutide
Outcome
No significant changeChange in LVEF from baseline to week 24 (LIVE trial)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
In the LIVE trial, the change in the left ventricular ejection fraction (LVEF) from baseline to week 24 was not significantly different between treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764405
06HumanSystematic reviewSafety outcome
In adults with heart failure and reduced ejection fraction, 29% of liraglutide patients discontinued treatment in the FIGHT trial.
In plain wordsIn the FIGHT trial in people with heart failure, 29% stopped liraglutide.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuation rate in the FIGHT trial
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
discontinuation rate
29%
FIGHT trial
Source sentences
Summary
The overall discontinuation rate of liraglutide was high in the FIGHT trial (29%, 86) as compared to that in the LIVE trial (11.6%, 28).
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764406
07HumanSystematic reviewSafety outcome
In adults with heart failure and reduced ejection fraction, 11.6% of liraglutide patients discontinued treatment in the LIVE trial.
In plain wordsIn the LIVE trial in people with heart failure, 11.6% stopped liraglutide.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuation rate in the LIVE trial
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
discontinuation rate
11.6%
LIVE trial
Source sentences
Summary
The overall discontinuation rate of liraglutide was high in the FIGHT trial (29%, 86) as compared to that in the LIVE trial (11.6%, 28).
2 context sentences(design, population, supporting numbers)
Summary · context
We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
Summary · context
Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
Report a problemFND-3286764407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.